Actively Recruiting

Phase 2
Age: 10Years +
All Genders
ID06551844

Adaptive Dengue Antiviral Platform Trial (ADAPT): Randomized, Open-Label Study of Antiviral Drugs for Early Dengue Infection

Led by Oxford University Clinical Research Unit, Vietnam · Updated on 2026-04-30

500

Participants Needed

2

Research Sites

52 weeks

Total Duration

On this page

Sponsors

O

Oxford University Clinical Research Unit, Vietnam

Lead Sponsor

H

Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the antiviral effects of several experimental drugs in patients with early dengue infection, defined as those with confirmed dengue and less than 48 hours of fever. This adaptive platform trial aims to determine how well these drugs work against the dengue virus and assess their safety and tolerability. The study also explores how these drugs affect various physiological and clinical markers in dengue patients. Participants are randomly assigned to one of four groups: standard care with no study drug, molnupiravir taken orally twice daily for five days, a single intravenous dose of a dengue monoclonal antibody called VIS513, or remdesivir dosed according to weight over five days. The trial is open-label and adaptive, allowing for the addition of new treatments or removal of less effective ones based on ongoing results. During the trial, participants will be monitored from randomization through day 5 for viral clearance and safety, with further follow-up visits at 30 and 60 days after enrollment. Researchers will assess virus levels, fever duration, clinical progression, and laboratory measures such as platelet count and liver enzymes. Safety events and adverse effects are also tracked up to 30 days post-enrollment to ensure participant well-being throughout the study.

CONDITIONS

Brief Title

Adaptive Dengue Antiviral Platform Trial

Who Can Participate

Age: 10Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of dengue virus infection with less than 48 hours of fever
  • Positive NS1 rapid diagnostic test
  • Age 10 years or older (or 18 years depending on drug license)
  • Able to provide written informed consent or assent
  • Willing to stay in hospital for about 5 days and attend follow-up visits on days 30 and 60 post-enrollment
Not Eligible

You will not qualify if you...

  • Severe dengue at baseline, including shock, severe bleeding, or organ failure
  • Pregnant or breastfeeding women
  • Signs of other infections such as pneumonia or sepsis
  • Renal failure with eGFR less than 30 ml/min
  • Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic, or immunosuppressive disorders
  • Known allergies or hypersensitivity to study drug components (mild allergies allowed)
  • Any condition that may complicate participation or safety
  • Participation in another investigational drug study within the past month

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 48 hours since onset of fever

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit (in-person)

Treatment

Duration - 5 days

Participants receive one of several antiviral treatments or standard care for early dengue infection.

Daily visits or hospital stay for about 5 days

Follow-up

Duration - Up to 60 days post-enrollment

Participants are monitored for safety and recovery after treatment completion.

2 follow-up visits at approximately 30 and 60 days post-enrollment

Trial Site Locations

Total: 2 locations

1

Universiti Malaya Medical Centre

Kuala Lumpur, Malaysia, 59100

Not Yet Recruiting

2

Hospital for Tropical Diseases, Ho Chi Minh city

Ho Chi Minh City, Vietnam, 700000

Actively Recruiting

Loading map...

Research Team

S

Sophie Yacoub, MD., PhD.

C

Clinical Trials Unit Oxford University Clinical Research Unit

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here